Authorization

AtriCure Announces Pricing of Public Offering of Common Stock

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for
atrial fibrillation (Afib) and left atrial appendage (LAA) management,
today announced the pricing of its underwritten offering of 2.5 million
shares of its common stock at a price to the public of $30.75 per share
pursuant to its existing shelf registration statement. Net proceeds to
AtriCure from the offering are expected to beA approximately $72 million,
after deducting underwriting discounts and commissions and estimated
offering expenses. AtriCure has granted to the underwriters of the
offering a 30-day option to purchase up to an additional 375,000 shares
of common stock on the same terms and conditions. The offering is
expected to close on October 10, 2018, subject to customary closing
conditions. AtriCure intends to use the net proceeds from the offering
for working capital and other general corporate purposes, which may
include repayment of debt, the possible pursuit of strategic
acquisitions, and other potential corporate or market development
activities.


J.P. Morgan and Piper Jaffray & Co. are acting as joint book-running
managers for the offering. Canaccord Genuity LLC, Leerink Partners, and
Stifel, Nicolaus & Company, Incorporated are acting as co-managers.


A shelf registration statement on Form S-3 relating to the common stock
offered in the underwritten offering described above was declared
effective by the Securities and Exchange Commission (SEC) on June 24,
2016. The offering is being made only by means of a written prospectus
and prospectus supplement that form a part of the registration
statement. A preliminary prospectus supplement has been filed with the
SEC and is available on the SECa??s website atA www.sec.gov.
A final prospectus supplement will be filed with the SEC. Copies of the
preliminary prospectus supplement and accompanying prospectus, and when
available, copies of the final prospectus supplement and the
accompanying prospectus, may also be obtained by contacting J.P. Morgan
Securities LLC, Attention:A Broadridge Financial Solutions,A 1155 Long
Island Avenue,A Edgewood, NYA 11717, or by phone at 1-866-803-9204, or by
email at prospectus-eq_fi@jpmchase.com;
or Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet
Mall, J12S03, Minneapolis, MN 55402, or by telephone at 800-747-3924, or
by email at prospectus@pjc.com.


This press release shall not constitute an offer to sell or the
solicitation of an offer to buy the securities being offered, nor shall
there be any sale of the securities being offered in any state or other
jurisdiction in which such offer, solicitation or sale would be unlawful
prior to the registration or qualification under the securities laws of
any such state or other jurisdiction.
See also:
Leave a comment
News
  • Latest
  • Read
  • Commented
Calendar Content
«    Октябрь 2019    »
ПнВтСрЧтПтСбВс
 123456
78910111213
14151617181920
21222324252627
28293031